Bio-Techne Showcases New Biomarker Data from Regulus Therapeutics Using Proprietary Technology

Bio-Techne Corporation and Regulus Therapeutics Inc. have announced continued collaboration following positive results from Regulus' Phase 1b multiple ascending dose (MAD) study of RGLS8429, aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The collaboration, initiated in 2020, focuses on supporting biomarker analysis for the development of anti-miR-17 therapies.

Regulus has leveraged Bio-Techne's Simple WesternTM platforms and ExosomeDx CLIA laboratory to produce the recently reported clinical data. Simple Western technology enables automated western blotting for efficient identification and quantification of therapeutic proteins. Bio-Techne's ExosomeDx specializes in liquid biopsy diagnostics, facilitating the isolation and analysis of exosomes to measure RNA, cell-free DNA, and proteins.

The Simple Western platform was used by Regulus to develop sensitive biomarker assays to measure polycystin 1 (PC1) and polycystin 2 (PC2) levels in urine samples. These proteins are crucial mechanistic and pharmacodynamic indicators in ADPKD, a condition characterized by low levels of PC1 and PC2. The testing is conducted at Bio-Techne's ExosomeDx CLIA laboratory, taking full advantage of their exosome expertise and clinical testing capabilities.

Will Geist, President of Bio-Techne’s Protein Sciences Segment, congratulated the Regulus team for their milestone achievement and expressed eagerness to continue working with them in the next study phase. Geist emphasized Bio-Techne’s commitment to enabling biotech companies to develop advanced therapeutics that contribute to global healthcare improvements.

Bio-Techne Corporation, a global life sciences company listed on NASDAQ under the ticker symbol TECH, provides innovative tools and bioactive reagents for research and clinical diagnostics. The company’s extensive product portfolio supports scientific research into biological processes and disease progression, aids in drug discovery, and ensures accurate clinical testing and diagnostics. In fiscal 2023, Bio-Techne reported over $1.1 billion in net sales and employs around 3,100 people globally.

Regulus Therapeutics Inc., headquartered in San Diego, CA, is a biopharmaceutical company dedicated to discovering and developing innovative drugs targeting microRNAs. Their expertise in oligonucleotide drug discovery and development has resulted in a robust pipeline and a strong intellectual property portfolio in the microRNA field.